Correction to: Cardiovasc Diabetol (2017) 16:128 https://doi.org/10.1186/s12933-017-0610-y
Following publication of the original article [1], the authors submitted a corrected version of Table 4 (see below), as the original version contained a mistake.
Table 4
Comparison of outcome results from terminated CVOTs in comparison to placebo
SAVOR-TIMI53 [1, 2] | EXAMINE [3, 4] | TECOS [5] | ELIXA [6] | EMPA-REG OUTCOME [7] | LEADER [8] | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Class | HR (95% CI) | Class | HR (95% CI) | Class | HR (95% CI) | Class | HR (95% CI) | Class | HR (95% CI) | Class | HR (95% CI) | |
p value | p value | p value | p value | p value | p value | |||||||
Cardiovascular endpoints | ||||||||||||
Primary composite MACE | CV death, MI, or stroke | 1.00 (0.89–1.12) 0.99 | CV death, MI, or stroke | 0.96 (≤ 1.16) 0.32 | CV death, MI, UA, or stroke | 0.98 (0.89–1.08) 0.65 | CV death, MI, UA, or stroke | 1.02 (0.89–1.17) 0.81 | CV death, MI, or stroke | 0.86 (0.74–0.99) 0.04a
| CV death, MI, or stroke | 0.87 (0.78–0.97) 0.01 |
Cardiovascular death | Primary endpoint | 1.03 (0.87–1.22) 0.72 | Primary endpoint | 0.79 (0.60–1.04) 0.10 | Secondary endpoint | 1.03 (0.89–1.19) 0.71 | Primary endpoint | 0.98 (0.78–1.22) 0.85 | Primary endpoint | 0.62 (0.49–0.77) < 0.001 | Primary endpoint | 0.78 (0.66–0.93) 0.007 |
Myocardial infarction | Primary endpoint | 0.95 (0.80–1.12) 0.52 | Primary endpoint | 1.08 (0.88–1.33) 0.47 | Secondary endpoint | 0.95 (0.81–1.11) 0.49 | Primary endpoint | 1.03 (0.87–1.22) 0.71 | Primary endpoint | 0.87 (0.70–1.09) 0.23 | Primary endpoint | 0.86 (0.73–1.00) 0.046 |
Stroke | Primary endpoint | 1.11 (0.88–1.39) 0.38 | Primary endpoint | 0.91 (0.55–1.50) 0.71 | Secondary endpoint | 0.97 (0.79–1.19) 0.76 | Primary endpoint | 1.12 (0.79–1.58) 0.54 | Primary endpoint | 1.18 (0.89–1.56) 0.26 | Primary endpoint | 0.86 (0.71–1.06) 0.16 |
Hospitalization for unstable angina | Secondary endpoint | 1.19 (0.89–1.60) 0.24 | Secondary endpoint | 0.90 (0.60–1.37) 0.632 | Secondary endpoint | 0.90 (0.70–1.16) 0.42 | Primary endpoint | 1.11 (0.47–2.62) 0.81 | Secondary endpoint | 0.99 (0.74–1.34) 0.97 | Extended primary endpoint | 0.98 (0.76–1.26) 0.87 |
Hospitalization for heart failure | Secondary endpoint | 1.27 (1.07–1.51) 0.007 | Extended primary endpoint | 1.19 (0.90–1.58) 0.220 | Secondary endpoint | 1.00 (0.83–1.20) 0.98 | Secondary endpoint | 0.96 (0.75–1.23) 0.75 | Secondary endpoint | 0.65 (0.50–0.85) 0.002 | Extended primary endpoint | 0.87 (0.73–1.05) 0.14 |
Event rate (%) active group | Event rate (%) active group | Event rate (%) active group | Event rate (%) active group | Event rate (%) active group | Event rate (%) active group | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Primary composite MACE | 7.3 | 11.3 | 9.6 | 13.4 | 10.5 | 13.0 |
No. (%) p value | No. (%) p value | No. (%) p value | No. (%) p value | No. (%) p value | No. (%) p value | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Non-cardiovascular endpoints | ||||||||||||
Renal event | 5.8 0.04 | 0.9 0.88 | 1.4 – | 1.6 – | 5.2 – | 5.7 0.003 | ||||||
Acute pancreatitis | 0.3 0.77 | 0.4 0.5 | 0.3 0.07 | 0.2 – | 0.3b
– | 0.4 0.44 | ||||||
Hypoglycemia events | 15.3 < 0.001 | 6.7 0.74 | 2.2 0.33 | 16.6 0.14 | 2.8 | 2.4 0.02 | ||||||
SUSTAIN 6 [9] | EXSCEL [10] | DEVOTE [11] | CANVAS program [12] | ACE [13] | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
Class | HR (95% CI) p value | Class | HR (95% CI) p value | Class | HR (95% CI) p value | Class | HR (95% CI) p value | Class | HR (95% CI) p value | |
Cardiovascular endpoints | ||||||||||
Primary composite MACE | CV death, MI, or stroke | 0.74 (0.58–0.95) 0.02a
| CV death, MI or stroke | 0.91 (0.83–1.00) 0.06a
| CV death, MI or stroke | 0.91 (0.78–1.06) < 0.001 | CV death, MI or stroke | 0.86 (0.75–0.97) 0.02a
| CV death, MI, stroke, UA and HF | 0.98 (0.86–1.11) 0.73 |
Cardiovascular death | Primary endpoint | 0.98 (0.65–1.48) 0.92 | Secondary endpoint | 0.88 (0.76–1.02) | Primary endpoint | 0.96 (0.76–1.21) 0.71 | Primary endpoint | 0.87 (0.72–1.06) | Secondary endpoint | 0.89 (0.71–1.11) 0.29 |
Myocardial infarction | Primary endpoint | 0.74 (0.51–1.08) 0.12 | Secondary endpoint | 0.97 (0.85–1.10) | Primary endpoint | 0.85 (0.68–1.06) 0.15 | Primary endpoint | 0.89 (0.73–1.09) | Secondary endpoint | 1.12 (0.87–1.46) 0.38 |
Stroke | Primary endpoint | 0.61 (0.38–0.99) 0.04 | Secondary endpoint | 0.85 (0.70–1.03) | Primary endpoint | 0.90 (0.65–1.23) 0.50 | Primary endpoint | 0.87 (0.69–1.09) | Secondary endpoint | 0.97 (0.70–1.33) 0.83 |
Hospitalization for unstable angina | Extended primary endpoint | 0.82 (0.47–1.44) 0.49 | – | – | Primary endpoint | 0.95 (0.68–1.31) 0.74 | – | – | Secondary endpoint | 1.02 (0.82–1.26) 0.87 |
Hospitalization for heart failure | Extended primary endpoint | 1.11 (0.77–1.61) 0.57 | Secondary endpoint | 0.94 (0.78–1.13) | – | – | Secondary endpoint | 0.67 (0.52–0.87) | Secondary endpoint | 0.89 (0.63–1.24) 0.48 |
Event rate (%) active group | Event rate (%) active group | Event rate (%) active group | Event rate (%) active group | Event rate (%) active group | |
|---|---|---|---|---|---|
Primary composite MACE | 6.6 | 11.4 | 8.5 | 26.9d
| 14.4 |
No. (%) p value | No. (%) p value | No. (%) p value | No. (%) p value | No. (%) p value | |
|---|---|---|---|---|---|
Non-cardiovascular endpoints | |||||
Renal event | 3.9 – | 55 (0.7) | 3.8 – | 19.7d
0.32 | – |
Acute pancreatitis | 0.55 – | 26 (0.4) | – – | 0.5d
0.63 | – |
Hypoglycemia events | 22.4c
– | 247 (3.4) | 4.9 < 0.001a
| 56.0d
0.20 | 54 (2) 0.95 |
The original article has been corrected.
Anzeige
References
1.
Leiter LA, et al. Efficacy and safety of saxagliptin in older participants in the SAVOR-TIMI 53 trial. Diabetes Care. 2015;38(6):1145–53.
2.
Scirica BM, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369(14):1317–26.
3.
White WB, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369(14):1327–35.
4.
Zannad F, et al. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet. 2015;385(9982):2067–76.
5.
Green JB, et al. Effect of sitagliptin on cardiovascular outcomes in Type 2 diabetes. N Engl J Med. 2015;373(3):232–42.
6.
Pfeffer MA, et al. Lixisenatide in patients with Type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373(23):2247–57.
7.
Zinman B, et al. Empagliflozin, cardiovascular outcomes, and mortality in Type 2 diabetes. N Engl J Med. 2015;373(22):2117–28.
8.
Marso SP, et al. Liraglutide and cardiovascular outcomes in Type 2 diabetes. N Engl J Med. 2016;375(4):311–22
9.
Marso SP, et al. Semaglutide and cardiovascular outcomes in patients with Type 2 diabetes. N Engl J Med. 2016;375(19):1834–44.
10.
Holman RR, et al. Effects of once-weekly exenatide on cardiovascular outcomes in Type 2 diabetes. N Engl J Med. 2017;377(13):1228–39.
11.
Marso SP, et al. Efficacy and safety of degludec versus glargine in Type 2 diabetes. N Engl J Med. 2017;377(8):723–32.
12.
Neal B, et al. Canagliflozin and cardiovascular and renal events in Type 2 diabetes. N Engl J Med. 2017;377(7):644-57.
13.
Holman RR, et al. Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2017;S2213-8587(17):30309–1.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.